Q/C Technologies, Inc. has filed a report detailing significant stock transactions involving PharmaCyte Biotech, Inc. This development is noteworthy as it reflects the ongoing consolidation trends in the in vitro and in vivo diagnostic substances industry. The exchange of shares and warrants could have implications for both companies and the broader market.
Background
Q/C Technologies, Inc. operates in the in vitro and in vivo diagnostic substances sector, classified under SIC code 2835. The company trades on the Nasdaq under the ticker symbol QCLS. Recent filings indicate a series of transactions and updates, including a Schedule 13D/A and an 8-K, which highlight its ongoing activities and strategic direction.
What the Filing Says
The recent filing reveals that on November 18, 2026, PharmaCyte Biotech, Inc. exchanged 4,982,272 shares of common stock for 851,304 Series G Long-Term Warrants as part of a Consent and Warrant Exchange Agreement. The filing states, "The number of shares of Common Stock issued was determined based on the Black Scholes value of the exchanged warrants divided by $0.3101 per share, the closing price of the Common Stock on the last trading day prior to execution of the Consent Agreement." Following this transaction, PharmaCyte now holds a total of 13,318,344 shares of Q/C Technologies, Inc.
Impact
This transaction may affect both companies significantly. For Q/C Technologies, the increase in shares held by PharmaCyte could lead to changes in governance and strategic direction. The in vitro and in vivo diagnostic substances industry may also see shifts as companies adapt to the evolving landscape shaped by such transactions.
What's Next
The filing does not say what happens next.
Read Next
Devereaux Terah L Disposes of Shares in Regency Centers Corp
Ondas Inc. Director Jaspreet Sood Reports Stock Transactions
Enovis Corp's Chief HR Officer Reports Stock Transaction
Boundless Bio's Kevin Tang Increases Stock Holdings Significantly
Huston Robert Patrick Reports Stock Transactions at Ondas Inc.
Ondas Inc. Director Reports Stock Transactions in SEC Filing




